BenevolentAI Investor Day Presentation Deck

Agenda Market Context - Al-enabled drug discovery Dr Ivan Griffin, COO The BenevolentAl Business Model Dr Ivan Griffin, COO Our Approach and Technology Dr Daniel Neil, CTO Olly Oechsle, whiteboard animation of the Benevolent Platform™ - Drug Discovery and Pipeline Review Dr Anne Phelan, CSO Professor Tom MacDonald - Immunology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London Interim Results 2022 - H1 Review & Financials Nick Keher, CFO Closing remarks & Outlook Joanna Shields CEO Q&A Benevolent 10

View entire presentation